- Home
- Equipment
- usa massachusetts
- cell therapy for cellular therapy
Show results for
Refine by
Cell Therapy For Cellular Therapy Equipment Supplied In Usa Massachusetts
22 equipment items found
Manufactured by:Obsidian Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Engineered with membrane-bound IL15, Eliminates toxic IL2 regimen, increasing patient accessibility to TIL therapy, Drives improved persistence, IL15 expression controlled by acetazolamide (ACZ), via cytoDRiVE® ...
Manufactured by:Ardigen based inKraków, POLAND
Accelerate discovery and improve safety of TCR therapies using Artificial Intelligence. Following the unique opportunity for curing patients provided by the development of cell therapies (e.g. TCR discovery), Ardigen has set on the path to advance the field with its Artificial Intelligence platform. Many challenges stand in the way of successful therapy discovery and development. Let us know how ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Licensed from the National Institutes of Health, VCAR33 is a CD33-directed chimeric antigen receptor T cell (CAR-T) therapy. A T cell therapy using the same CAR construct as VCAR33 is being studied in a multi-site Phase 1/2 clinical trial as an autologous monotherapy bridge-to-transplant for relapsed and/or refractory AML patients, sponsored by the National Marrow Donor Program ...
Manufactured by:Editas Medicine based inCambridge, MASSACHUSETTS (USA)
Genomic medicine is a developing field of medical research that harnesses recent advances in genetics to develop new medicines for diseases. In fact, we are at an inflection point where we are seeing the first real genomic medicines emerge to help patients. Advances in the scientific fields of cell therapy and gene therapy have paved the way for the success of gene editing, which in turn is now ...
Manufactured by:Advanced Instruments based inNorwood, MASSACHUSETTS (USA)
MatriClone is a new matrix designed to support iPSC growth in single seeding workflows while maintaining pluripotency. MatriClone is optimized for ‘in-solution’ seeding and optically suited for automated imaging. When used as part of the VIPS seeding protocol, MatriClone offers high levels of single cell survival and subsequent outgrowth, all in a simple, automated workflow which ...
Manufactured by:JPT Peptide Technologies GmbH based inBerlin, GERMANY
Neo-epitopes are important targets for individualized cancer immunotherapy. Recent advancements in next generation sequencing and bioinformatic approaches to predict immunogenicity of neo-epitopes improved target selection for therapy. However, in many cases only a fraction of predicted epitopes generate a specific T-cell response. Therefore, various assay techniques such as ELISpot, ...
Manufactured by:Cytena based inFreiburg, GERMANY
Faster than Ever Before: By automating labor-intensive and time-consuming steps, the F.SIGHT 2.0 significantly streamlines Cell Line Development (CLD), Cell & Gene therapy, as well as Single-cell Omics workflows. The F.SIGHT 2.0 is the fastest single-cell dispenser that isolates both unlabeled and green fluorescent cells. With our patented, highly efficient and gentle single-cell technology, ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through a rapid, single-day cell process. This method provides significant advantages to the patient, contract development, and manufacturing organizations ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
Our lead clinical stage natural killer (NK) cell therapy, is an autologous platform technology that activates NK cells to kill cancers expressing a unique membrane form of Heat Shock Protein 70 ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
An autologous mHsp70 targeted NK Cell Therapy that activates NK cells to target and kill cells expressing mHsp70. The therapy begins with selecting patients whom have high mHsp70 expression with our Companion Diagnostic AP-CDx (described below), collecting their peripheral blood mononuclear cells (PBMCs) by leukapheresis, ex vivo activation of PBMCs with our synthetic Hsp70-derived peptide ...
Manufactured by:Verax Biomedical, Incorporated based inMarlborough, MASSACHUSETTS (USA)
Stem cells, activated leukocytes and other cellular therapies are another area of obvious applicability for PGD technology as these cells are grown in media that also support bacterial proliferation. As with platelets and red blood cells, current techniques for the detection of contaminating bacteria before ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures. In preclinical studies, we have observed that the removal of CD33 ...
Manufactured by:JPT Peptide Technologies GmbH based inBerlin, GERMANY
Clinical peptides and PepMix Peptide Pools are increasingly needed as antigen source for clinical immune monitoring, diagnostics, cell therapy and vaccine development. The diversity of applications and regulatory requirements calls for a flexible, high quality peptide partner. JPT is that partner with its outstanding know-how on peptide antigen formats, peptide specifications and formulation, ...
by:Aegle Therapeutics based inWoburn, MASSACHUSETTS (USA)
Aegle’s founder Dr. Evangelos Badiavas and his team have spent decades researching clinical applications of mesenchymal stem cells (“MSCs”) in severe dermatological disorders, including conducting clinical trials in burns and wounds under multiple INDs. In these trials, patients experienced accelerated healing, little to no scarring, total wound closure and tissue regeneration. ...
Manufactured by:Editas Medicine based inCambridge, MASSACHUSETTS (USA)
EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, where naturally occurring fetal hemoglobin (HbF) inducing mutations reside, by a ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation ...
Manufactured by:Ardigen based inKraków, POLAND
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to generate and prioritize antigen targets for cancer vaccines and T-cell ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
An allogenic NK cell therapy that targets tumors expressing mHsp70. Patients are selected with high mHsp70 exosomes in their blood using our Companion Diagnostic AP-CDx (described below). We obtain PBMCs from healthy donors by apheresis, their NK cells are expanded, and incubated ex vivo with TKD and IL-2, followed by freezing, thawing and intravenous administration to ...
Premium
Manufactured by:AB Sciex LLC based inFramingham, MASSACHUSETTS (USA)
Perform consistent and compliant biotherapeutics characterization faster than ever. With the PA 800 Plus system, you can confidently safeguard the success of your biologics. Run multiple characterizations from a single system that biopharma labs depend on, and produce qualitative and quantitative analyses, with speed and ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas ...